RU2010130355A - MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS - Google Patents

MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS Download PDF

Info

Publication number
RU2010130355A
RU2010130355A RU2010130355/15A RU2010130355A RU2010130355A RU 2010130355 A RU2010130355 A RU 2010130355A RU 2010130355/15 A RU2010130355/15 A RU 2010130355/15A RU 2010130355 A RU2010130355 A RU 2010130355A RU 2010130355 A RU2010130355 A RU 2010130355A
Authority
RU
Russia
Prior art keywords
antibodies
activated
aqueous
potentiated
endothelial
Prior art date
Application number
RU2010130355/15A
Other languages
Russian (ru)
Other versions
RU2530638C2 (en
Inventor
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Original Assignee
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2010130355/15A priority Critical patent/RU2530638C2/en
Application filed by Олег Ильич Эпштейн (RU), Олег Ильич Эпштейн filed Critical Олег Ильич Эпштейн (RU)
Priority to SE1350184A priority patent/SE1350184A1/en
Priority to PCT/IB2011/002364 priority patent/WO2012014078A2/en
Priority to FR1156481A priority patent/FR2962914A1/en
Priority to CZ20130105A priority patent/CZ2013105A3/en
Priority to PCT/IB2011/002350 priority patent/WO2012007845A2/en
Priority to EA201300126A priority patent/EA030566B1/en
Priority to ES201390006A priority patent/ES2440393R1/en
Priority to SG2013002324A priority patent/SG187038A1/en
Priority to US13/135,896 priority patent/US20120258146A1/en
Priority to SG10201505561TA priority patent/SG10201505561TA/en
Priority to PE2013000076A priority patent/PE20130398A1/en
Priority to IT000634A priority patent/ITTO20110634A1/en
Priority to AU2011278038A priority patent/AU2011278038B2/en
Priority to BR112013000840A priority patent/BR112013000840A2/en
Priority to NZ606767A priority patent/NZ606767A/en
Priority to EEP201300006A priority patent/EE201300006A/en
Priority to MX2013000543A priority patent/MX2013000543A/en
Priority to EP11775839.1A priority patent/EP2596020A2/en
Priority to GB1302649.7A priority patent/GB2495884B/en
Priority to JP2013519175A priority patent/JP2013538186A/en
Priority to EP11775838.3A priority patent/EP2593140A2/en
Priority to DE112011102358T priority patent/DE112011102358T5/en
Priority to CA2804966A priority patent/CA2804966A1/en
Priority to FR1156482A priority patent/FR2962656A1/en
Priority to KR1020137003861A priority patent/KR20140014059A/en
Priority to IT000639A priority patent/ITTO20110639A1/en
Priority to US13/135,901 priority patent/US9308275B2/en
Priority to ARP110102578A priority patent/AR082247A1/en
Publication of RU2010130355A publication Critical patent/RU2010130355A/en
Priority to CL2013000099A priority patent/CL2013000099A1/en
Priority to NO20130222A priority patent/NO20130222A1/en
Priority to LT2013016A priority patent/LT5988B/en
Priority to DKPA201370079A priority patent/DK201370079A/en
Priority to FI20135143A priority patent/FI20135143L/en
Application granted granted Critical
Publication of RU2530638C2 publication Critical patent/RU2530638C2/en
Priority to US15/060,202 priority patent/US20160251448A1/en
Priority to US15/060,157 priority patent/US20160244531A1/en
Priority to JP2016135750A priority patent/JP2016216483A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. Лекарственное средство для лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза, содержащее активированную-потенцированную форму антител к мозгоспецифическому белку S-100, характеризующееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного-усиливающего компонента активированную-потенцированную форму антител к эндотелиальной NO-синтазе. ! 2. Лекарственное средство по п.1, характеризующееся тем, что активированную-потенцированную форму антител к эндотелиальной NO-синтазе и активированную-потенцированную форму антител к мозгоспецифическому белку S-100 используют в виде активированного-потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения. ! 3. Лекарственное средство по п.1 или 2, характеризующееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью водных или водно-спиртовых растворов активированной-потенцированной формы антител к эндотелиальной NO-синтазе и активированной-потенцированной формы антител к мозгоспецифическому белку S-100, и фармацевтически приемлемые добавки. ! 4. Лекарственное средство по п.1 или 2, характеризующееся тем, что водные или водно-спиртовые растворы активированных потенцированных форм антител к эндотелиальной NO-синтазе и к мозгоспецифическ� 1. A medicine for the treatment of organic diseases of the nervous system, psycho-organic syndrome and encephalopathies of various genesis, containing an activated-potentiated form of antibodies to the brain-specific protein S-100, characterized in that it is made in the form of a pharmaceutical composition and contains an activated- potentiated form of antibodies to endothelial NO synthase. ! 2. The drug according to claim 1, characterized in that the activated-potentiated form of antibodies to endothelial NO synthase and the activated-potentiated form of antibodies to brain-specific protein S-100 are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution, the activity of which due to the process of successive multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. ! 3. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of aqueous or aqueous-alcoholic solutions of an activated-potentiated form of antibodies to endothelial NO synthase and activated -potentiated forms of antibodies to the brain-specific protein S-100, and pharmaceutically acceptable additives. ! 4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of activated potentiated forms of antibodies to endothelial NO synthase and to brain-specific

Claims (9)

1. Лекарственное средство для лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза, содержащее активированную-потенцированную форму антител к мозгоспецифическому белку S-100, характеризующееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного-усиливающего компонента активированную-потенцированную форму антител к эндотелиальной NO-синтазе.1. A medicine for the treatment of organic diseases of the nervous system, psycho-organic syndrome and encephalopathies of various genesis, containing an activated-potentiated form of antibodies to the brain-specific protein S-100, characterized in that it is made in the form of a pharmaceutical composition and contains an activated- potentiated form of antibodies to endothelial NO synthase. 2. Лекарственное средство по п.1, характеризующееся тем, что активированную-потенцированную форму антител к эндотелиальной NO-синтазе и активированную-потенцированную форму антител к мозгоспецифическому белку S-100 используют в виде активированного-потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.2. The drug according to claim 1, characterized in that the activated-potentiated form of antibodies to endothelial NO synthase and the activated-potentiated form of antibodies to brain-specific protein S-100 are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution, the activity of which due to the process of successive multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. 3. Лекарственное средство по п.1 или 2, характеризующееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью водных или водно-спиртовых растворов активированной-потенцированной формы антител к эндотелиальной NO-синтазе и активированной-потенцированной формы антител к мозгоспецифическому белку S-100, и фармацевтически приемлемые добавки.3. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of aqueous or aqueous-alcoholic solutions of an activated-potentiated form of antibodies to endothelial NO synthase and activated -potentiated forms of antibodies to the brain-specific protein S-100, and pharmaceutically acceptable additives. 4. Лекарственное средство по п.1 или 2, характеризующееся тем, что водные или водно-спиртовые растворы активированных потенцированных форм антител к эндотелиальной NO-синтазе и к мозгоспецифическому белку S-100 получены путем многократного последовательного разведения и внешнего воздействия - вертикального встряхивания каждого разведения из матричных растворов аффинно-очищенных антител к эндотелиальной NO-синтазе и к мозгоспецифическому белку S-100 с концентрацией 0,5÷5,0 мг/мл.4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of activated potentiated forms of antibodies to endothelial NO synthase and to brain-specific protein S-100 are obtained by repeated serial dilution and external exposure - vertical shaking of each dilution from matrix solutions of affinity-purified antibodies to endothelial NO synthase and to the brain-specific protein S-100 with a concentration of 0.5 ÷ 5.0 mg / ml. 5. Лекарственное средство по п.1 или 2, характеризующееся тем, что каждый из компонентов на основе сверхмалых доз аффинно-очищенных антител используют в виде смеси различных, преимущественно сотенных, разведений по гомеопатической технологии.5. The drug according to claim 1 or 2, characterized in that each of the components based on ultra-low doses of affinity-purified antibodies is used as a mixture of various, mainly hundred, dilutions according to homeopathic technology. 6. Лекарственное средство по п.3, характеризующееся тем, что фармацевтически приемлемые добавки включают лактозу, целлюлозу микрокристаллическую и магния стеарат.6. The drug according to claim 3, characterized in that the pharmaceutically acceptable additives include lactose, microcrystalline cellulose and magnesium stearate. 7. Способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза путем введения в организм активированной-потенцированной формы антител к мозгоспецифическому белку S-100, характеризующийся тем, что дополнительно одновременно и сочетано вводят активированную-потенцированную форму сверхмалых доз аффинно-очищенных антител к эндотелиальной NO-синтазе.7. A method for the treatment of organic diseases of the nervous system, psycho-organic syndrome and encephalopathies of various genesis by introducing into the body an activated-potentiated form of antibodies to the brain-specific protein S-100, characterized in that an activated-potentiated form of ultra-low doses of affinity-purified antibodies is additionally simultaneously combined. to endothelial NO synthase. 8. Способ по п.7, характеризующийся тем, что активированную-потенцированную форму антител к эндотелиальной NO-синтазе и активированную-потенцированную форму антител к мозгоспецифическому белку S-100 используют в виде активированного-потенцированного водного или водно-спиртового раствора каждого компонента, активность которого обусловлена процессом многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.8. The method according to claim 7, characterized in that the activated-potentiated form of antibodies to endothelial NO synthase and the activated-potentiated form of antibodies to brain-specific protein S-100 are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution of each component, activity which is due to the process of multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. 9. Способ лечения по п.7 или 8, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы смесь различных разведений антител к эндотелиальной NO-синтазе в сочетании со смесью различных разведении антител к мозгоспецифическому белку S-100, приготовленных по гомеопатической технологии. 9. The treatment method according to claim 7 or 8, characterized in that they use a mixture of different dilutions of antibodies to endothelial NO synthase prepared in the form of a single drug - one dosage form in combination with a mixture of different dilutions of antibodies to brain-specific protein S-100 prepared by homeopathic technology.
RU2010130355/15A 2010-07-15 2010-07-21 Medication and method of treating organic diseases of nervous system, psychoorganic syndrome and encephalopathies of different genesis RU2530638C2 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
RU2010130355/15A RU2530638C2 (en) 2010-07-21 2010-07-21 Medication and method of treating organic diseases of nervous system, psychoorganic syndrome and encephalopathies of different genesis
JP2013519175A JP2013538186A (en) 2010-07-15 2011-07-15 Method for increasing the effect of activation-enhancing antibodies
FR1156481A FR2962914A1 (en) 2010-07-21 2011-07-15 PHARMACEUTICAL COMPOSITION FOR USE IN A PROCESS FOR TREATING NERVOUS SYSTEM ORGANIC DISEASES, PSYCHO-ORGANIC SYNDROME AND ENCEPHALOPATHY
CZ20130105A CZ2013105A3 (en) 2010-07-15 2011-07-15 Method of increasing effect of antibody activated potentiated form
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EA201300126A EA030566B1 (en) 2010-07-15 2011-07-15 Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition
ES201390006A ES2440393R1 (en) 2010-07-15 2011-07-15 A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
SG2013002324A SG187038A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
US13/135,896 US20120258146A1 (en) 2010-07-21 2011-07-15 Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
SG10201505561TA SG10201505561TA (en) 2010-07-15 2011-07-15 A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
PE2013000076A PE20130398A1 (en) 2010-07-15 2011-07-15 A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY
IT000634A ITTO20110634A1 (en) 2010-07-21 2011-07-15 METHOD FOR TREATING ORGANIC DISEASES OF THE NERVOUS SYSTEM, THE PSYCHOORGANIC SYNDROME AND THE SYNTHALOPATHY
AU2011278038A AU2011278038B2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EP11775838.3A EP2593140A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
NZ606767A NZ606767A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EEP201300006A EE201300006A (en) 2010-07-15 2011-07-15 A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody
MX2013000543A MX2013000543A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
EP11775839.1A EP2596020A2 (en) 2010-07-21 2011-07-15 Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
SE1350184A SE1350184A1 (en) 2010-07-15 2011-07-15 PROCEDURE TO INCREASE THE EFFECT OF AN ACTIVATED, POTENTIZED FORM OF AN ANTIBODY
GB1302649.7A GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PCT/IB2011/002364 WO2012014078A2 (en) 2010-07-21 2011-07-15 Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
DE112011102358T DE112011102358T5 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CA2804966A CA2804966A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
FR1156482A FR2962656A1 (en) 2010-07-15 2011-07-15 METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
KR1020137003861A KR20140014059A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
IT000639A ITTO20110639A1 (en) 2010-07-15 2011-07-15 METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY
US13/135,901 US9308275B2 (en) 2010-07-15 2011-07-15 Method of increasing the effect of an activated-potentiated form of an antibody
BR112013000840A BR112013000840A2 (en) 2010-07-15 2011-07-15 method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
ARP110102578A AR082247A1 (en) 2010-07-15 2011-07-18 A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
CL2013000099A CL2013000099A1 (en) 2010-07-15 2013-01-10 A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it.
NO20130222A NO20130222A1 (en) 2010-07-15 2013-02-08 Process for increasing the effect of an activated-potentiated form of an antibody
LT2013016A LT5988B (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
DKPA201370079A DK201370079A (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
FI20135143A FI20135143L (en) 2010-07-15 2013-02-15 A method of increasing the potency of an activated potentiated form of an antibody
US15/060,202 US20160251448A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
US15/060,157 US20160244531A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
JP2016135750A JP2016216483A (en) 2010-07-15 2016-07-08 Method of increasing effect of activated-potentiated antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010130355/15A RU2530638C2 (en) 2010-07-21 2010-07-21 Medication and method of treating organic diseases of nervous system, psychoorganic syndrome and encephalopathies of different genesis

Publications (2)

Publication Number Publication Date
RU2010130355A true RU2010130355A (en) 2012-01-27
RU2530638C2 RU2530638C2 (en) 2014-10-10

Family

ID=45786202

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010130355/15A RU2530638C2 (en) 2010-07-15 2010-07-21 Medication and method of treating organic diseases of nervous system, psychoorganic syndrome and encephalopathies of different genesis

Country Status (1)

Country Link
RU (1) RU2530638C2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
RU2156621C1 (en) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Neurotropic drug

Also Published As

Publication number Publication date
RU2530638C2 (en) 2014-10-10

Similar Documents

Publication Publication Date Title
RU2010133048A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
JP2013538195A5 (en)
RU2010133045A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2011127052A (en) METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT
RU2010133053A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2010130356A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF VEGETO-VASCULAR DYSTONIA, VERTAIN SYNDROME OF VARIOUS GENESIS AND KINETOSIS
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2013154070A (en) METHOD FOR TREATMENT OF VEGETAIN-VASCULAR DISTONIA AND MEDICINAL PRODUCT
RU2010130358A (en) MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME
RU2010130353A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2013154072A (en) MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
RU2010129295A (en) MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES
RU2010130350A (en) METHOD FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING AND MEDICINAL PRODUCT FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING
RU2013154073A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A PATHOLOGICAL SYNDROME
RU2010133052A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL INFECTIONS AND METHOD OF TREATMENT OF VIRAL INFECTIONS
RU2011124809A (en) MEDICINE FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING FUNCTIONAL INTESTINAL DISORDERS
RU2011127056A (en) MEDICINAL PRODUCT FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING MULTIPLE SCLEROSIS
RU2013152874A (en) MEDICINE
RU2010129294A (en) MEDICINE FOR TREATMENT OF ERECTILE DYSFUNCTIONS AND METHOD OF TREATMENT OF ERECTILE DYSFUNCTIONS
RU2010131386A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190722